Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Guy Ezekiel
AddedMar 31, 2024
UpdatedMay 31, 2026
Guy Ezekiel

Guy Ezekiel

Founder, Marval Pharma

CrunchbaseLinkedIn

Guy Ezekiel's Career

Marval Pharma
Marval Pharma

San Diego, CA, US

Founder
Zorro
Zorro

New York City, NY, US

Co-Founder & CEO· C-Suite · Management
Variantyx
Variantyx

Framingham, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Guy Ezekiel's Career

Marval Pharma
Marval Pharma
Seed$7.1M52007San Diego, CA, US
Founder

Similar to Marval Pharma

Rapidscan Pharma SolutionsRapidscan Pharma SolutionsLos Altos, CA, USStress Agentsest. 2010Rapidscan Pharma SolutionsLos Altos, CA, US · est. 2010

Rapidscan Pharma Solutions Inc. develops pharmacological stress agents for diagnosing cardiovascular diseases.

Series A · $2.4M7
Reveal PharmaceuticalsReveal PharmaceuticalsCambridge, MA, USMRI Contrast Agentsest. 2016Reveal PharmaceuticalsCambridge, MA, US · est. 2016

Supplying gadolinium-free MRI contrast agents for essential medical imaging needs.

Pre-Seed · $4.1M8
Biomarck PharmaceuticalsBiomarck PharmaceuticalsDurham, NC, USTherapeuticsest. 2002Biomarck PharmaceuticalsDurham, NC, US · est. 2002

Bismarck Pharmaceuticals: A Durham-based biotech firm innovating in inflammatory and immunological disease treatment.

Public · $15.5M14
Imagen BiotechImagen BiotechNew York City, NY, USTherapeuticsest. 2011Imagen BiotechNew York City, NY, US · est. 2011

Imagen Biotech: Pioneering solutions for blinding diseases through innovative therapeutics.

Series A · $40M30
Zorro
Zorro
Investment Firm$11.5M362022New York City, NY, US
Co-Founder & CEO· C-Suite · Management

Leadership at Zorro

Maya PerlMaya PerlCo-Founder
Cindy D.Cindy D.Co-Founder
Variantyx
Variantyx
Late Stage Private$100.5M1662014Framingham, MA, US
Board Member· Board

Leadership at Variantyx

Zafi AvnurZafi AvnurBoard Member
Noam ShomronNoam ShomronCo-Founder
Tomer JackmanTomer JackmanCo-Founder
Haim NeermanHaim NeermanCo-Founder

Similar to Variantyx

Variant BioVariant BioSeattle, WA, USTherapeuticsest. 2018Variant BioSeattle, WA, US · est. 2018

Variant Bio: Harnessing human genetic diversity for innovative therapeutic discovery.

Series B · $129.7M42
Genome InsightGenome InsightSan Diego, CA, USGenome Sequencingest. 2020Genome InsightSan Diego, CA, US · est. 2020

Genome Insight: Expert in whole genome sequence analysis and interpretation.

Series B · $52.7M57
InvitaeInvitaeSan Francisco, CA, USGenetic Testingest. 2010InvitaeSan Francisco, CA, US · est. 2010

Invitae Corp., a global genetic information company, specializes in diagnostics, oncology, pediatrics, and hereditary screening.

Public · $2.5B1.7k
GenomenonGenomenonAnn Arbor, MI, USData, Softwareest. 2014GenomenonAnn Arbor, MI, US · est. 2014

Genomenon: Comprehensive genomic evidence provider, aiding in critical biomarker identification.

Series B · $32.8M80

People Similar to Guy Ezekiel

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakHaeil YiHaeil YiCo-Founder · DunamuLee Sirg-OoLee Sirg-OoCEO · DunamuIan McChordIan McChordFounder · Collective IntelligenceZak GroveZak GroveCo-Founder · Zoro CardAaron JacobsonAaron JacobsonPartner · New Enterprise AssociatesAvishai ShohamAvishai ShohamCo-Founder · EvozElon BomsElon BomsBoard Member · LaunchCapital